常规疫苗接种与新发特发性葡萄膜炎风险的关联
一项美国多医疗系统回顾性队列研究显示,接种COVID-19、HPV、水痘、重组带状疱疹或活带状疱疹疫苗者,在接种后3、6、12个月新发特发性葡萄膜炎风险均低于倾向评分匹配的未接种对照。排除既往相应病毒感染诊断后结果相似。
要点
- 所有受试疫苗均与12个月内新发特发性葡萄膜炎风险降低相关。
- 水痘疫苗风险比最低(RR 0.29),HPV疫苗最高(RR 0.44)。
- 排除既往相应病毒感染后,风险降低趋势仍相似。
核心结论
- 接种COVID-19、HPV、水痘、重组带状疱疹或活带状疱疹疫苗与新发特发性葡萄膜炎风险降低相关。
研究设计与样本
- 回顾性队列研究,使用美国多个医疗系统的汇总电子健康记录。
- 纳入2006至2025年接种COVID-19、HPV、水痘、重组带状疱疹或活带状疱疹疫苗者及倾向评分匹配对照。
主要发现
- 所有受试疫苗在接种后12个月内均与新发特发性葡萄膜炎风险降低相关。
- COVID-19疫苗相对风险降低65%(RR 0.35;95%CI 0.33-0.37)。
- HPV疫苗相对风险降低56%(RR 0.44;95%CI 0.35-0.54)。
- 水痘疫苗相对风险降低71%(RR 0.29;95%CI 0.25-0.33)。
- 活带状疱疹疫苗相对风险降低68%(RR 0.32;95%CI 0.23-0.43),重组带状疱疹疫苗相对风险降低69%(RR 0.31;95%CI 0.26-0.37)。
关键数值与推荐
- 主要结局为接种后3、6、12个月新发特发性葡萄膜炎发病率。
- 计算总体及亚型(前、中间、后、全葡萄膜炎)的风险比及95%置信区间。
- 排除既往相应病毒感染诊断后重复分析,结果相似。
临床怎么用
- 眼科医生评估新发特发性葡萄膜炎时,可将近期疫苗接种史作为免疫调节背景信息纳入考量。
- 接种上述疫苗可能与较低的特发性葡萄膜炎风险相关,但不应据此改变疫苗接种建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association between vaccination and the risk of new-onset idiopathic uveitis (NIU). DESIGN: Retrospective cohort study of aggregated electronic health records from multiple health systems across the United States. SUBJECTS: Subjects who received the coronavirus disease 2019 (COVID-19), human papillomavirus (HPV), varicella, recombinant herpes zoster, or live herpes zoster vaccinations from 2006 to 2025 and propensity-score matched controls. INTERVENTION: Vaccines against COVID-19, HPV, varicella, recombinant herpes zoster, or live herpes zoster. MAIN OUTCOMES AND MEASURES: The main outcome was the incidence of NIU at 3, 6, and 12 months following vaccination. Vaccinated patients were compared with matched controls who did not receive the respective vaccines. Analyses were repeated, excluding patients with previous diagnosis of the respective viral infection. Risk ratios (RR) with 95% confidence intervals (CIs) were calculated for overall NIU and constituent subtypes (anterior, intermediate, posterior, and panuveitis). RESULTS: All tested vaccinations were associated with reduced risk of NIU through 12 months compared with matched controls. Relative risk reductions were 65% for COVID-19 (RR, 0.35; CI, 0.33-0.37), 56% for HPV (RR, 0.44; CI, 0.35-0.54), 71% for varicella (RR, 0.29; CI, 0.25-0.33), 68% for live zoster (RR, 0.32; CI, 0.23-0.43), and 69% for recombinant zoster vaccination (RR, 0.31; CI, 0.26-0.37). Similar reductions were observed after excluding patients with prior diagnoses of the respective viral infections. CONCLUSIONS: Vaccination was associated with a lower risk of idiopathic uveitis, representing the complex interplay between immune modulation and the development of NIU.
引用
- Schulgit MJ, Bala S, Bellanda V, et al. Associations Between Routine Vaccinations and the Risk of New-Onset Idiopathic Uveitis. Am J Ophthalmol. 2026. PMID: 42336229. doi:10.1016/j.ajo.2026.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。